Scynexis (SCYX) Non Operating Income (2013 - 2026)
Scynexis (SCYX) posted Non Operating Income of -$4.4 million for Q1 2026, down 351.01% on a QoQ basis from $1.7 million in Q4 2025, and down 235.45% year-over-year from $3.2 million in Q1 2025.
Scynexis (SCYX) Non Operating Income (2013 - 2026) Analysis & Trends
Scynexis' Non Operating Income history runs 14 years deep, the most recent figure standing at -$4.4 million for Q1 2026.
- Quarterly Non Operating Income fell 235.45% year-over-year to -$4.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$133000.0 (down 101.52% YoY) and the FY2025 annual result came in at $7.5 million, down 53.29% from the prior year.
- Non Operating Income was -$4.4 million for Q1 2026 at Scynexis, down from $1.7 million in the prior quarter.
- Across five years, Non Operating Income topped out at $10.4 million in Q1 2024 and bottomed at -$23.2 million in Q1 2023.
- A 5-year average of $1.9 million and a median of $3.6 million in 2023 frame the typical range for Non Operating Income.
- Annual changes were most pronounced in 2022 — Non Operating Income jumped 583.7% — and 2023, when it sank 341.93%.
- Scynexis' Non Operating Income stood at $8.1 million in 2022, then plunged by 55.08% to $3.6 million in 2023, then grew by 0.72% to $3.6 million in 2024, then slumped by 52.32% to $1.7 million in 2025, then sank by 351.01% to -$4.4 million in 2026.
- Business Quant data shows SCYX's Non Operating Income at -$4.4 million in Q1 2026, $1.7 million in Q4 2025, and -$186000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | -216.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 20.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -7.50 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 53.40 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Scynexis | 21.55 Mn | -15.20 Mn | - | -4.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.36 Mn |
| Dec 31, 2025 | 1.74 Mn |
| Sep 30, 2025 | -186,000.00 |
| Jun 30, 2025 | 2.68 Mn |
| Mar 31, 2025 | 3.22 Mn |
| Dec 31, 2024 | 3.64 Mn |
| Sep 30, 2024 | 7.12 Mn |
| Jun 30, 2024 | -5.22 Mn |
| Mar 31, 2024 | 10.45 Mn |
| Dec 31, 2023 | 3.62 Mn |
| Sep 30, 2023 | 8.34 Mn |
| Jun 30, 2023 | 5.75 Mn |
| Mar 31, 2023 | -23.19 Mn |
| Dec 31, 2022 | 8.05 Mn |
| Sep 30, 2022 | -7.78 Mn |
| Jun 30, 2022 | 8.39 Mn |
| Mar 31, 2022 | 9.59 Mn |
| Dec 31, 2021 | -6.95 Mn |
| Sep 30, 2021 | 18.79 Mn |
| Jun 30, 2021 | 15.03 Mn |